🚨 #ESMO26 | OptiTROP-Lung04 (Phase III- China only trial)

Significant mOS 8.5 mo advantage for sac-TMT, a TROP2 ADC, after EGFR-TKI progression in EGFR-mutant NSCLC🫁 vs chemo!

📊 Median OS: 25.9 vs 17.4 months
🔥 HR 0.69 — 31% lower risk of death
⚠️ AEs- cytopenias, stomatitis, opthal, ILD

👉🏽Competes w Dato-DXd already approved in this EGFR+ population based on Tropion-Lung05, Lung01
👉🏽Global validation and treatment-sequencing questions remain.
@EGFRResisters
#LCSM #LungCancer #ESMO26